Pegfilgrastim

(Neulasta®)

Pegfilgrastim

Drug updated on 9/14/2023

Dosage FormInjection (subcutaneous; : 6 mg/0.6 mL)
Drug ClassLeukocyte growth factor
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
  • Indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome).

Product Monograph / Prescribing Information

Document TitleYearSource
Neulasta (pegfilgrastim) Prescribing Information.2021Amgen Inc., Thousand Oaks, California

Systematic Reviews / Meta-Analyses